Dyax - Advancing Novel Biotherapeutics

Dedicated to finding new solutions for patients in need.

SEC Filings

Form 4
DYAX CORP filed this Form 4 on Jun 25, 2010
Document Outline
Entire Document (17.8 KB)
Subdocument 1 - 4 - Statement of changes in beneficial ownership of securities
Page 1 - FORM 4

Stock quote

ExchangeNASDAQ (US Dollar)
Price$2.32
Change (%) Stock is Down 0.03 (1.28%)

Investor Relations Contacts

Ivana Magovcevic-Liebisch
Executive Vice President Corporate Development and General Counsel
Dyax Corp.
Phone: 617-225-2500


Nicole Jones
Director, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500


JENNIFER VIERA
Manager, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500